Eagle Eye i am trying to focus away from mining/resources to some extent because it has attracted too much capital and promotional operators
some of these bio's interest me, well nto so much binary bio's but medical stuff
so Angle (AGL) with the cancer diagnostics
this micro cap CARE (CareCapital) is interesting from transformational news perspective because it'll change name to Advanced Oncotherapy and actually has treatments now which seem established so ready commercial market and could become quite a hot story if marketed right
also lots of big names in stock tipping circles like Mellon and Bulford seem to be moving into bios/medical stuff so I think they may be onto something
CARE recent RNS
Formation of Oncotherapy Resources Limited
Second Innovative Cancer Treatment to be Launched in the UK
CareCapital (AIM: CARE) announces the formation of Oncotherapy Resources Limited ("Oncotherapy Resources"), a Company registered in England, that will provide a managed service to early stage breast cancer patients in the UK NHS, Ireland and private treatment centres. The service will be based on exclusive access to the Xoft Axxent Electronic Brachytherapy System® ("the Xoft System"). CareCapital will own 75% of Oncotherapy Resources with the balance held equally by two companies, the principal European distributor of the XoftSystem, Pergentium Ltd, and Duncan Hynd Associates Ltd, a leader in the distribution of advanced radiotherapy products and a pioneer in the provision of prostate seed implants as a service. CareCapital will have the right to acquire the 25% of Oncotherapy Resources that it does not own after four years.
The Xoft System uses an electronic X-ray source instead of a radioactive isotope to deliver radiation internally. The low energy and rapid dose fall-off of the electronic source allow for treatment in rooms with reduced shielding requirements compared to conventional radiation therapy. The Xoft System can be used for both high dose rate brachytherapy and for intraoperative radiation therapy ("IORT"). IORT provides clinicians the option to perform radiotherapy in the operating room at the time of lumpectomy.
The Xoft System is lightweight and mobile and can be moved easily between treatment locations. This means that it can overcome the logistical challenges faced by many patients who may have to travel long distances to access conventional radiotherapy. The managed service to be provided by Oncotherapy Resources has the potential to benefit the NHS by enabling patients to receive therapy locally and more cost-effectively due to the reduced need for shielding (allowing clinical staff to remain with the patient during treatment) and, in the case of IORT, the ability to provide a one-off dose rather than the conventional daily radiotherapy for up to six weeks. There are around 20,000 patients annually receiving lumpectomy surgery in the UK, of which most would benefit from the Xoft System.
In the UK private sector, for-profit providers who are seeking to offer radiotherapy closer to the patient, or which wish to offer a complete range of state-of-the-art treatments in one centre, the ability to offer an electronic brachytherapy system for IORT could be an attractive proposition. Private providers could also refer patients to Oncotherapy Resources' managed service but provide it at their own centres due to the portability of the Xoft System.
The Xoft System has recently seen the first installation in Europe (in Germany) and there are 62 operational sites in the United States.
Commenting on Oncotherapy Resources, Dr Michael Sinclair, Chairman of CareCapital, said, "This ticks all the boxes for patients - accessibility, usability and cost effectiveness - while still delivering the same outcomes as conventional radiotherapy.
"From CareCapital's viewpoint, it also ticks all the boxes - a proven, state-of-the-art cancer therapy already successfully in operation and a good strategic fit alongside proton beam therapy into what I hope will become our growing portfolio of innovative cancer treatments."
http://fool.uk-wire.com/Article.aspx?id=201203130705232257Z
Restructuring, Proposed Change of Name
Changes to Senior Management and Board Responsibilities
Care Capital announces a restructuring to reflect its strategy to reposition the Group primarily as an investor in, and provider of, advanced cancer treatments.
Current investments in medical centre development projects are to be transferred to the Group's wholly owned subsidiary - The Healthcare Property Company Limited - which will continue to progress existing schemes and expand through securing new medical centre projects in the UK. This company will also provide property related support services to the wider Group.
The Company also announces that it will be seeking shareholder authority at the earliest opportunity to change its name to Advanced Oncotherapy plc.
http://fool.uk-wire.com/Article.aspx?id=201203280700142138A
